Foley Partner Gardner Davis and Senior Counsel Danielle Whitley authored an article titled “NOL and void” in the April 5, 2010 issue of The Deal. The authors discuss a Delaware Court of Chancery decision that upheld Selectica Inc.’s selection of a shareholder rights plan, or poison pill, as a tool to protect its net operating loss carry forwards (NOLs), remarking that it is the first time that a Delaware court has reviewed a board’s decision to adopt a poison pill intended to guard NOLs. They add that the decision should not be interpreted as support for the suggestion that a board can safely adopt a poison pill in every circumstance, noting the court’s acknowledgment that shareholder rights plans must be subject to careful review.
Author(s)
Related Insights
July 10, 2025
Foley Viewpoints
One Big Beautiful Bill Act Permanently Increases the Lifetime Estate, Gift and GST Tax Exclusion
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (OBBBA). The OBBBA extended and may permanent many key…
July 10, 2025
Foley Viewpoints
FTC's "Click-to-Cancel" Rule Invalidated
The Federal Appeals Court for the 8th Circuit invalidated the Federal Trade Commission's (FTC) “click-to-cancel” (aka “negative option”)…
July 10, 2025
Foley Viewpoints
Trump Administration Passes the One Big Beautiful Bill Act
On July 4, 2025, President Trump signed H.R. 1—referred to as the One Big Beautiful Bill Act (OBBBA). The OBBBA extends and makes…